{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:09:20Z","timestamp":1781762960046,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1157506"],"award-info":[{"award-number":["GNT1157506"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1196900"],"award-info":[{"award-number":["GNT1196900"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40801-022-00322-6","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T16:02:45Z","timestamp":1659801765000},"page":"639-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-9397","authenticated-orcid":false,"given":"Jodie Belinda","family":"Hillen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ty","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. E.","family":"Roughead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kalisch\u202fEllett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:2042098620938595.","journal-title":"Ther Adv Drug Saf."},{"issue":"10","key":"322_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2165\/11316550-000000000-00000","volume":"32","author":"TJ Giezen","year":"2009","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf. 2009;32(10):811\u20137.","journal-title":"Drug Saf"},{"issue":"6","key":"322_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.535","volume":"7","author":"MS Castelli","year":"2019","unstructured":"Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6): e00535.","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"322_CR4","first-page":"148","volume":"39","author":"E Dotan","year":"2010","unstructured":"Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma. Pharm Ther. 2010;39(3):148\u201357.","journal-title":"Pharm Ther"},{"issue":"11","key":"322_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40264-018-0684-9","volume":"41","author":"Y Ingrasciotta","year":"2018","unstructured":"Ingrasciotta Y, Cutroneo PM, Marcian\u00f2 I, Giezen T, Atzeni F, Trifir\u00f2 G. Safety of biologics, including biosimilars: perspectives on current status and future direction. Drug Saf. 2018;41(11):1013\u201322.","journal-title":"Drug Saf"},{"issue":"4","key":"322_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18773\/austprescr.2016.053","volume":"39","author":"KL Randall","year":"2016","unstructured":"Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39(4):131\u20134.","journal-title":"Aust Prescr"},{"issue":"7","key":"322_CR7","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3174\/ajnr.A2142","volume":"31","author":"DT Selewski","year":"2010","unstructured":"Selewski DT, Shah GV, Mody RJ, Rajdev PA, Mukherji SK. Rituximab (Rituxan). Am J Neuroradiol. 2010;31(7):1178\u201380.","journal-title":"Am J Neuroradiol"},{"issue":"4","key":"322_CR8","first-page":"105","volume":"11","author":"A Rafiee Zadeh","year":"2019","unstructured":"Rafiee Zadeh A, Ghadimi K, Ataei A, Askari M, Sheikhinia N, Tavoosi N, et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. Int J Physiol Pathophysiol Pharmacol. 2019;11(4):105\u201314.","journal-title":"Int J Physiol Pathophysiol Pharmacol."},{"key":"322_CR9","unstructured":"Therapeutic Goods Administration. Database of adverse event notifications. Medicine Summary (Rituximab). Institution: Department of Health 2020; Canberra: Australian Government. 2020."},{"issue":"2","key":"322_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13221","volume":"33","author":"P Aggarwal","year":"2020","unstructured":"Aggarwal P. Pyoderma gangrenosum adverse event with rituximab use: a postmarketing pharmacovigilance analysis. Dermatol Ther. 2020;33(2): e13221.","journal-title":"Dermatol Ther"},{"issue":"9","key":"322_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/j.1468-3083.2009.03199.x","volume":"23","author":"E Ruocco","year":"2009","unstructured":"Ruocco E, Sangiuliano S, Gravina AJ, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23(9):1008\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"322_CR12","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.19909.1","volume":"8","author":"J Fletcher","year":"2019","unstructured":"Fletcher J, Alhusayen R, Alavi A. Recent advances in managing and understanding pyoderma gangrenosum. F1000 Res. 2019;8:F1000 Faculty Rev-2092.","journal-title":"F1000 Res"},{"issue":"3655","key":"322_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bmj.333.7560.181","volume":"333","author":"T Brookly","year":"2006","unstructured":"Brookly T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333(3655):181\u20134.","journal-title":"BMJ"},{"issue":"6","key":"322_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.12968\/jowc.2019.28.Sup6.S1","volume":"28","author":"K Isoherranen","year":"2019","unstructured":"Isoherranen K, O\u2019Brien JJ, Barker J, Dissemond J, Hafner J, Jemec GBE, et al. Atypical wounds: best clinical practices and challenges. An EWMA document. J Wound Care. 2019;28(6):S1-92.","journal-title":"J Wound Care"},{"issue":"2","key":"322_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/wsbm.1323","volume":"8","author":"MR Boland","year":"2016","unstructured":"Boland MR, Jacunski A, Lorberbaum T, Romano JD, Moskovitch R, Tatonetti NP. Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms. Wiley Interdiscip Rev Syst Biol Med. 2016;8(2):104\u201322.","journal-title":"Wiley Interdiscip Rev Syst Biol Med."},{"issue":"11","key":"322_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40264-014-0224-1","volume":"37","author":"PM Cutroneo","year":"2014","unstructured":"Cutroneo PM, Isgro V, Russo A, Ientile V, Sottosanti L, Pimpinella G, et al. Safety profile of biological medicines as compared with non-biologicals: an analysis of the Italian spontaneous reporting system database. Drug Saf. 2014;37(11):961\u201370.","journal-title":"Drug Saf"},{"issue":"8","key":"322_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/10408444.2018.1518404","volume":"48","author":"LA Cox","year":"2018","unstructured":"Cox LA. Modernizing the Bradford Hill criteria for assessing causal relationships in observational data. Crit Rev Toxicol. 2018;48(8):682\u2013712.","journal-title":"Crit Rev Toxicol"},{"issue":"4","key":"322_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.chembiol.2013.03.017","volume":"20","author":"M Duran-Frigola","year":"2013","unstructured":"Duran-Frigola M, Aloy P. Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem Biol. 2013;20(4):594\u2013603.","journal-title":"Chem Biol"},{"key":"322_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5313","author":"I Frent","year":"2021","unstructured":"Frent I, Busca C, Leucuta D, Farcas A, Mogosan C. An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: a VigiBase study. Pharmacoepidemiol Drug Saf. 2021;30(10):1428\u201340. https:\/\/doi.org\/10.1002\/pds.5313.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"322_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/cpt.2","volume":"97","author":"T Lorberbaum","year":"2015","unstructured":"Lorberbaum T, Nasir M, Keiser MJ, Vilar S, Hripcsak G, Tatonetti NP. Systems pharmacology augments drug safety surveillance. Clin Pharmacol Ther. 2015;97(2):151\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"322_CR21","unstructured":"US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) quarterly data extract files."},{"key":"322_CR22","volume-title":"FDA adverse event reporting system (FAERS) public dashboard","author":"US Food and Drug Administration (FDA)","year":"2022","unstructured":"US Food and Drug Administration (FDA). FDA adverse event reporting system (FAERS) public dashboard. Silver Spring: Department of Health and Human Services; 2022."},{"key":"322_CR23","unstructured":"Medical Dictionary for Regulatory Activities (MeDRA) 2020. https:\/\/www.meddra.org\/browsers. Accessed 8 Jul 2022."},{"key":"322_CR24","unstructured":"Ontology NCfB. Medical Dictionary for Regulatory Activities terminology (MedDRA). BioPortal: National Centres for Biomedical Computing; 2021. https:\/\/bioportal.bioontology.org\/ontologies\/MEDDRA?p=summary. Accessed 8 Jul 2022."},{"key":"322_CR25","unstructured":"OHDSI. The book of OHDSI. Chapter 4: the common data model. https:\/\/ohdsi.github.io\/TheBookOfOhdsi\/CommonDataModel. Accessed 8 Jul 2022."},{"key":"322_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.32614\/RJ-2014-011","volume":"6","author":"M van der Loo","year":"2014","unstructured":"van der Loo M. The stringdist package for approximate string matching. R J. 2014;6:111\u201322.","journal-title":"R J"},{"key":"322_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jbi.2016.02.009","volume":"60","author":"H Ibrahim","year":"2016","unstructured":"Ibrahim H, Saad A, Abdo A, Sharaf EA. Mining association patterns of drug-interactions using post marketing FDA\u2019s spontaneous reporting data. J Biomed Inform. 2016;60:294\u2013308.","journal-title":"J Biomed Inform"},{"issue":"7","key":"322_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pds.771","volume":"12","author":"AL Gould","year":"2003","unstructured":"Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003;12(7):559\u201374.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"322_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"322_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","volume":"25","author":"A Bate","year":"2002","unstructured":"Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393\u20137.","journal-title":"Drug Saf"},{"issue":"21","key":"322_CR31","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","volume":"25","author":"GN Nor\u00e9n","year":"2006","unstructured":"Nor\u00e9n GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006;25(21):3740\u201357.","journal-title":"Stat Med"},{"issue":"6","key":"322_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577\u201387.","journal-title":"Drug Saf"},{"issue":"6","key":"322_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"322_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","volume":"39","author":"HH Ji","year":"2019","unstructured":"Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig. 2019;39(3):319\u201330.","journal-title":"Clin Drug Investig"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00322-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00322-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00322-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:33:34Z","timestamp":1669836814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00322-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00322-6","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"26 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by the National Health and Medical Research Council (NHMRC) Project Grant GNT1157506 and GNT1196900. EE Roughead\u00a0is funded\u00a0under NHRMC GNT1110139.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jodie Belinda Hillen, Ty Stanford, Michael Ward, EE Roughead, Lisa Kalisch Ellett and Nicole Pratt have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"This research was approved by the University of South Australia Human Research Ethics Committee\u00a0(Application ID: 201902).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available from the FAERS Public Dashboard.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code is available at .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JBH and NP developed the study protocol, analysed the data and drafted the manuscript. TS extracted the FAERS data, conducted the risk analyses and drafted the manuscript.\u00a0MW contributed to the study protocol and interpreting the data. EER and LKE\u00a0contributed to the study protocol and drafting of the manuscript.\u00a0All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}